Densitas’ Machine Learning Software for Breast Health Available On EnvoyAI PlatformNov 27, 2017
DM-Density personalized breast density reporting software will be offered via vendor-neutral artificial intelligence distribution platform
Chicago, IL – November 26, 2017 – Advanced breast imaging analytics provider, Densitas®, today announced that it now offers its automated breast density software through EnvoyAI’s scalable distribution platform to facilitate streamlined deployment of its flagship product within hospital networks and clinics. The software, DM-Density, helps radiologists provide tailored, patient-specific follow-up care.
“We’re pleased to offer hospitals and physicians the opportunity to use Densitas’ breast density software either on-premise or in the cloud. We’re committed to providing our customer base with secure access to innovative AI products globally,” said Misha Herscu, CEO, EnvoyAI. “Densitas’ breast density software is a welcome addition to the many clinically useful applications available on the EnvoyAI Exchange.”
“We’re pleased to partner with EnvoyAI to streamline deployment of our automated breast density software to empower health systems to standardize high quality care for women and improve workflow,” said Mo Abdolell, CEO, Densitas®. “The EnvoyAI platform provides a unique opportunity to rapidly expand our footprint so these important outcomes can be achieved.”
DM-Density is a machine learning application that provides on demand automated breast density assessments at point-of-care. The software analyzes standard digital mammograms and integrates seamlessly with PACS systems. The reports provide radiologists with insights to make better follow-up care decisions consistently and confidently.
Densitas® develops machine learning technologies that deliver actionable information for personalized breast health. The technologies address the key challenges facing breast screening, including mammography quality, workflow, compliance and costs, with the aim of improving patient health efficiently and effectively. Densitas® has received regulatory clearance to sell its automated breast density assessment software in Canada and the European Union. www.densitashealth.ca
EnvoyAI provides a developer platform, integrations, and an API interface for algorithm developers, technology partners, and end users. EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. The platform allows users anywhere to access cloud-based algorithms without requiring access to the algorithm code or training data to protect PHI and developer intellectual property. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialization processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians. www.envoyai.com
Director, Programs and Regulatory Affairs